Recently, PI3Kα inhibitor alpelisib was approved in combination with fulvestrant for advanced/metastatic PIK3CA-mutated HR-positive HER2-negative breast cancer in postmenopausal women and men. The gene discussed is ERBB2; the disease is breast carcinoma.